Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:6354 |
Name | chronic lymphocytic leukemia/small lymphocytic lymphoma |
Definition | A chronic lymphocytic leukemia that is characterized by the presence of immature lymphocytes in the blood and bone marrow and/or in the lymph nodes. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 mutant | Ibrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Ibrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Rituximab + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Rituximab + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Idelalisib + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Idelalisib + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | N/A | chronic lymphocytic leukemia/small lymphocytic lymphoma | not applicable | detail... |
TP53 mutant | N/A | chronic lymphocytic leukemia/small lymphocytic lymphoma | not applicable | detail... |
TP53 loss | Obinutuzumab + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Obinutuzumab + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Acalabrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Acalabrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Duvelisib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Duvelisib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Zanubrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | predicted - sensitive | detail... |
TP53 loss | Acalabrutinib + Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Acalabrutinib + Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Alemtuzumab + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Alemtuzumab + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Methylprednisolone + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Methylprednisolone + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Idelalisib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Idelalisib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Lenalidomide + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Lenalidomide + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Zanubrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Pirtobrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Pirtobrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Methylprednisolone + Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Methylprednisolone + Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Ibrutinib + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Ibrutinib + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT01125176 | Phase II | Lenalidomide + Rituximab + Thalidomide | Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL | Completed | USA | 0 |
NCT01253460 | Phase II | Cyclophosphamide Rituximab + Sapacitabine | Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) | Terminated | USA | 0 |
NCT01353625 | Phase I | CC-115 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | Completed | USA | FRA | ESP | DEU | 0 |
NCT01796171 | Phase Ib/II | Lilotomab Betalutin Rituximab | A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS | 15 |
NCT01804686 | Phase III | Ibrutinib | A Long-term Extension Study of PCI-32765 (Ibrutinib) | Enrolling by invitation | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 21 |
NCT01811368 | Phase II | anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT01886859 | Phase I | Ibrutinib + Lenalidomide | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Completed | USA | 0 |
NCT01976585 | Phase Ib/II | CDX-301 + Poly ICLC | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | Completed | USA | 0 |
NCT01994382 | Phase I | Cerdulatinib | Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma | Completed | USA | 0 |
NCT02000934 | Phase I | Mivavotinib | A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies | Completed | USA | ITA | GBR | ESP | 0 |
NCT02005289 | Phase II | Lenalidomide + Tafasitamab-cxix Ibrutinib + Tafasitamab-cxix | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL | Active, not recruiting | USA | 0 |
NCT02006485 | Phase I | Ublituximab + Umbralisib Ibrutinib | Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies | Completed | USA | 0 |
NCT02007044 | Phase II | Ibrutinib Ibrutinib + Rituximab | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02029443 | Phase Ib/II | Acalabrutinib | ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia | Active, not recruiting | USA | ITA | GBR | 0 |
NCT02160015 | Phase I | Ibrutinib + Lenalidomide + Rituximab | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02254772 | Phase Ib/II | Ipilimumab + SD-101 | TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | Completed | USA | 0 |
NCT02266147 | Phase Ib/II | SD-101 | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | Terminated | USA | 0 |
NCT02296918 | Phase I | Acalabrutinib + Obinutuzumab | ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL | Active, not recruiting | USA | 0 |
NCT02329847 | Phase Ib/II | Ibrutinib + Nivolumab | Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies | Completed | USA | ESP | AUS | 3 |
NCT02337829 | Phase II | Acalabrutinib | ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL | Active, not recruiting | USA | 0 |
NCT02339922 | Phase II | Ixazomib + Rituximab | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02381080 | Phase I | Erythromycin + Ibrutinib + Voriconazole | Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | Completed | ESP | CAN | 1 |
NCT02384954 | Phase Ib/II | ALT-803 + Rituximab | ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab | Terminated | USA | 0 |
NCT02406742 | Phase Ib/II | Obinutuzumab Rituximab Ibrutinib CC-122 | A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE) | Completed | USA | ITA | ESP | DEU | AUT | 0 |
NCT02420912 | Phase II | Ibrutinib + Nivolumab | Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Active, not recruiting | USA | GBR | FRA | 0 |
NCT02514083 | Phase II | Fludarabine + Ibrutinib | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | Active, not recruiting | USA | 0 |
NCT02518555 | Phase II | Ibrutinib | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Active, not recruiting | USA | 0 |
NCT02529813 | Phase I | Cyclophosphamide + Fludarabine + Tisagenlecleucel | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Completed | USA | 0 |
NCT02556931 | Phase II | Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | Completed | USA | 0 |
NCT02576275 | Phase III | Bendamustine + Rituximab Duvelisib | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | Withdrawn | USA | 0 |
NCT02614508 | Phase I | Buparlisib + Ibrutinib Buparlisib + Ofatumumab | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Terminated | USA | 0 |
NCT02626455 | Phase III | Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 26 |
NCT02629809 | Phase II | Cyclophosphamide + Fludarabine + Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab Ibrutinib | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02639910 | Phase II | Tafasitamab-cxix + Venetoclax Idelalisib + Tafasitamab-cxix | Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS) | Completed | USA | ITA | GBR | DEU | AUT | 1 |
NCT02640209 | Phase I | CART19 cells | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | Terminated | USA | 0 |
NCT02640833 | Phase I | Duvelisib + Venetoclax | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor | Withdrawn | USA | 0 |
NCT02662296 | Phase II | Idelalisib Ibrutinib | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | Withdrawn | USA | 0 |
NCT02677948 | Phase Ib/II | Ibrutinib + Pacritinib | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Withdrawn | USA | 0 |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Active, not recruiting | USA | 0 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT02756897 | Phase II | Ibrutinib + Venetoclax | Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | 0 |
NCT02787369 | Phase I | Idelalisib + Ricolinostat Ibrutinib + Ricolinostat | ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL | Active, not recruiting | USA | 0 |
NCT02825836 | Phase Ib/II | TL-895 | Phase I/II, First in Human, Dose Escalation Trial of TL 895 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma | Active, not recruiting | USA | ITA | GBR | 4 |
NCT02846623 | Phase II | Atezolizumab + Obinutuzumab + Venetoclax | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | Recruiting | USA | 0 |
NCT02867618 | Phase Ib/II | Carfilzomib + Umbralisib | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | Terminated | USA | 0 |
NCT02900716 | Phase I | DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus | Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | Completed | USA | 0 |
NCT02910583 | Phase II | Ibrutinib Ibrutinib + Venetoclax | Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | Active, not recruiting | USA | ITA | ESP | AUS | 2 |
NCT02914938 | Phase I | zandelisib Rituximab + zandelisib | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Terminated | USA | 1 |
NCT02924402 | Phase I | XmAb13676 | Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies | Recruiting | USA | GBR | FRA | 1 |
NCT02931110 | Phase I | CBL0137 | Study of IV CBL0137 in Previously Treated Hematological Subjects | Terminated | USA | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT02966756 | Phase II | Venetoclax | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Recruiting | AUS | 3 |
NCT03010358 | Phase Ib/II | Entospletinib + Obinutuzumab | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT03088878 | Phase Ib/II | Cirmtuzumab Cirmtuzumab + Ibrutinib Ibrutinib | A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | Active, not recruiting | USA | 0 |
NCT03104491 | Phase Ib/II | Inotuzumab ozogamicin | Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia and Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT03133221 | Phase II | Idelalisib | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03162536 | Phase I | ARQ 531 | Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03204188 | Phase II | Fludarabine + Ibrutinib + Pembrolizumab | Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Active, not recruiting | USA | 0 |
NCT03218683 | Phase I | AZD5991 | Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. | Terminated | USA | 0 |
NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | GBR | DEU | 1 |
NCT03331198 | Phase Ib/II | Lisocabtagene maraleucel Ibrutinib + Lisocabtagene maraleucel | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Active, not recruiting | USA | 0 |
NCT03336333 | Phase III | Venetoclax + Zanubrutinib Zanubrutinib Bendamustine + Rituximab | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | BEL | AUT | AUS | 7 |
NCT03370185 | Phase II | Duvelisib | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | Withdrawn | USA | 0 |
NCT03379493 | Phase I | Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | Terminated | USA | 0 | |
NCT03406156 | Phase III | Bendamustine + Obinutuzumab Obinutuzumab + Venetoclax Bendamustine | A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | Completed | USA | 0 |
NCT03422393 | Phase I | Ibrutinib + Venetoclax Venetoclax | Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib | Active, not recruiting | USA | 0 |
NCT03454165 | Phase I | BNC105P + Ibrutinib | A Study of BNC105P Combined With Ibrutinib | Completed | USA | 0 |
NCT03462719 | Phase III | Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW) | Active, not recruiting | USA | GBR | FRA | ESP | CAN | BEL | 8 |
NCT03479268 | Phase I | Ibrutinib + MLN4924 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03492125 | Phase I | MS-553 | A Study Of The Selective PKC-beta Inhibitor MS- 553 | Recruiting | USA | 0 |
NCT03498612 | Phase II | Pembrolizumab | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | Active, not recruiting | USA | 0 |
NCT03516617 | Phase II | Acalabrutinib Acalabrutinib + Obinutuzumab | Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT03534323 | Phase Ib/II | Duvelisib + Venetoclax | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL | Recruiting | USA | 0 |
NCT03547115 | Phase I | Voruciclib | A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies | Recruiting | USA | 0 |
NCT03557619 | Phase I | Ethinylestradiol + Levonorgestrel + Venetoclax | A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies | Recruiting | USA | AUS | 0 |
NCT03572634 | Phase Ib/II | Dubermatinib Dubermatinib + Ibrutinib | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL | Terminated | USA | 0 |
NCT03579888 | Phase I | CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine | CD19-Specific T Cells Post AlloSCT | Terminated | USA | 0 |
NCT03580928 | Phase II | Acalabrutinib + Obinutuzumab + Venetoclax | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO) | Active, not recruiting | USA | 0 |
NCT03625037 | Phase Ib/II | Epcoritamab-bysp | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE NHL-1) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 7 |
NCT03701282 | Phase III | Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab + Venetoclax | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 1 |
NCT03711578 | Phase II | Tenalisib | Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) | Completed | USA | AUS | 0 |
NCT03734016 | Phase III | Ibrutinib Zanubrutinib | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia | Active, not recruiting | 1 | |
NCT03740529 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Active, not recruiting | USA | ITA | GBR | FRA | AUS | 5 |
NCT03759184 | Phase I | Obinutuzumab + rhIL-15 | Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | Terminated | USA | 0 |
NCT03779113 | Phase Ib/II | HMPL-523 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | Recruiting | USA | ITA | FRA | ESP | 3 |
NCT03786926 | Phase Ib/II | HMPL-689 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | Active, not recruiting | USA | ITA | FRA | ESP | 2 |
NCT03788291 | Phase II | Acalabrutinib + Rituximab | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | Active, not recruiting | USA | 0 |
NCT03824483 | Phase II | Obinutuzumab + Venetoclax + Zanubrutinib | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | Recruiting | USA | 0 |
NCT03828448 | Phase II | Ublituximab + Umbralisib | Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naive Follicular Lymphoma | Terminated | USA | 0 |
NCT03884972 | Phase I | Trabectedin + Venetoclax | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor | Withdrawn | USA | 0 |
NCT03893682 | Phase I | CG-806 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | Active, not recruiting | USA | 0 |
NCT03960840 | Phase I | Ibrutinib + YTB323 YTB323 | CD19-specific CAR-T Cells in CLL/SLL and DLBCL | Recruiting | USA | ITA | FRA | ESP | DEU | AUT | AUS | 1 |
NCT03961672 | Phase II | Duvelisib | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Active, not recruiting | USA | 0 |
NCT04007029 | Phase I | Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04014205 | Phase I | Orelabrutinib | A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies | Active, not recruiting | USA | 3 |
NCT04018248 | Phase I | BR101801 | BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | Recruiting | USA | 1 |
NCT04038359 | Phase II | Duvelisib | A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO) | Completed | USA | ITA | GBR | DEU | 4 |
NCT04072458 | Phase I | BP1002 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Recruiting | USA | 0 |
NCT04116437 | Phase II | Zanubrutinib | A Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment With Ibrutinib | Recruiting | USA | 0 |
NCT04136275 | Phase I | Anti-CD37 CAR T cells | CAR-37 T Cells In Hematologic Malignancies | Recruiting | USA | 0 |
NCT04155840 | Phase II | Bendamustine + Copanlisib + Rituximab | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Terminated | USA | 0 |
NCT04160195 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | Terminated | USA | 0 |
NCT04169737 | Phase II | Acalabrutinib + Obinutuzumab + Venetoclax | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT04209621 | Phase II | Duvelisib + Ibrutinib | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Terminated | USA | 0 |
NCT04230304 | Phase II | Daratumumab + Ibrutinib | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study | Active, not recruiting | USA | 0 |
NCT04269902 | Phase III | Obinutuzumab + Venetoclax | Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study | Recruiting | USA | CAN | 0 |
NCT04277637 | Phase I | BGB-11417 + Zanubrutinib BGB-11417 | Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | Recruiting | USA | ITA | GBR | ESP | DEU | AUS | 1 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Recruiting | AUS | 1 |
NCT04401020 | Phase I | SAR442257 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | Recruiting | USA | ESP | 2 |
NCT04419519 | Phase II | Venetoclax | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | Recruiting | USA | 0 |
NCT04434196 | Phase I | CC-99282 + Obinutuzumab | A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Active, not recruiting | USA | ESP | CAN | AUT | 0 |
NCT04458610 | Phase II | Rituximab + Zanubrutinib | BTK Inhibitor Zanubrutinib (BGB-3111) in Combination With Rituximab for Previously Untreated Patient | Recruiting | USA | 0 |
NCT04501939 | Phase II | Cirmtuzumab + Venetoclax | Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax (Venetoclax) | Active, not recruiting | USA | 0 |
NCT04505254 | Phase II | Acalabrutinib + Obinutuzumab | Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04540796 | Phase I | JNJ-75348780 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | GBR | FRA | ESP | AUS | 3 |
NCT04545762 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04560322 | Phase II | Obinutuzumab + Venetoclax Ibrutinib + Obinutuzumab + Venetoclax | Venetoclax-Obinutuzumab +/- Ibrut in R/R CLL | Recruiting | USA | 0 |
NCT04578600 | Phase I | Azacitidine + Lenalidomide + Obinutuzumab | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04588922 | Phase I | GFH009 | A Study of GFH009 in Patients With Hematologic Malignancies | Recruiting | USA | 1 |
NCT04623541 | Phase Ib/II | Epcoritamab-bysp Epcoritamab-bysp + Venetoclax Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE CLL-1) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 4 |
NCT04624633 | Phase II | Acalabrutinib + Ublituximab + Umbralisib | AU2 In Relapsed and Untreated CLL | Active, not recruiting | USA | 0 |
NCT04657094 | Phase II | Acalabrutinib | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT04659044 | Phase II | Polatuzumab vedotin-piiq + Rituximab + Rituximab Hyaluronidase + Venetoclax Rituximab Hyaluronidase + Venetoclax | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04660045 | Phase II | Acalabrutinib | Early Intervention With Acalabrutinib in Patients With High Risk CLL | Withdrawn | USA | 0 |
NCT04665115 | Phase II | Ibrutinib | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | Withdrawn | USA | 0 |
NCT04666038 | Phase III | Idelalisib + Rituximab Pirtobrutinib Bendamustine + Rituximab | Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 14 |
NCT04685915 | Phase II | Copanlisib + Ibrutinib | Copanlisib Plus Ibrutinib in R/R CLL | Withdrawn | 0 | |
NCT04704323 | Phase I | CAP-100 | CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | Recruiting | USA | ESP | 0 |
NCT04722172 | Phase II | Acalabrutinib + Obinutuzumab | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | Active, not recruiting | USA | 0 |
NCT04728893 | Phase II | ARQ 531 | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 14 |
NCT04758975 | Phase II | Rituximab + Venetoclax Ibrutinib + Rituximab + Venetoclax | Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) (VALUABLE) | Recruiting | ITA | 0 |
NCT04763083 | Phase Ib/II | NVG-111 | First in Human Study of NVG-111 in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma | Recruiting | GBR | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04775745 | Phase I | LP-168 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | Recruiting | USA | 0 |
NCT04781855 | Phase I | Ibrutinib + Ipilimumab Ibrutinib + Ipilimumab + Nivolumab | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | Active, not recruiting | USA | 0 |
NCT04809467 | Phase Ib/II | Parsaclisib + Tafasitamab-cxix | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT04830137 | Phase I | NX-2127 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Active, not recruiting | USA | 0 |
NCT04843904 | Phase I | Obinutuzumab + Rituximab + Venetoclax | Safe Accelerated Venetoclax Escalation in CLL (SAVE) | Recruiting | USA | 0 |
NCT04853329 | Phase Ib/II | CPO107 | Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma | Suspended | USA | 0 |
NCT04861779 | Phase I | HSK29116 | A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | AUS | 1 |
NCT04908228 | Phase II | Ibrutinib + Obinutuzumab | Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naive Patients With CLL (FIGHT) | Recruiting | ITA | 0 |
NCT04941716 | Phase II | Acalabrutinib + Venetoclax | Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT04965493 | Phase III | Rituximab + Venetoclax Pirtobrutinib + Rituximab + Venetoclax | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 13 |
NCT04981912 | Phase I | Methylprednisolone + Rituximab | Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients | Active, not recruiting | USA | 0 |
NCT05003141 | Phase I | PSB202 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | Recruiting | USA | AUS | 1 |
NCT05006716 | Phase I | BGB-16673 | A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | 3 |
NCT05020678 | Phase I | Cyclophosphamide + Fludarabine NKX019 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Recruiting | USA | AUS | 0 |
NCT05023980 | Phase III | Pirtobrutinib Bendamustine + Rituximab | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313) | Recruiting | USA | ITA | GBR | FRA | ESP | AUT | AUS | 14 |
NCT05057494 | Phase III | Obinutuzumab + Venetoclax Acalabrutinib + Venetoclax | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC) | Recruiting | USA | FRA | ESP | AUS | 3 |
NCT05069051 | Phase II | Belimumab + Rituximab + Venetoclax | Belimumab in Patients With Chronic Lymphocytic Leukemia (BeliVeR) | Recruiting | DEU | 0 |
NCT05131022 | Phase I | NX-5948 | Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | GBR | 1 |
NCT05144347 | Phase I | XL114 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT05153330 | Phase I | BMF-219 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL With KMT2A/ MLL1r, NPM1 and Other Mutations | Recruiting | USA | ITA | ESP | 2 |
NCT05168930 | Phase II | Venetoclax + Zanubrutinib | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | Recruiting | USA | 0 |
NCT05172700 | Expanded access | Pirtobrutinib | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | Available | 0 | |
NCT05197192 | Phase III | Obinutuzumab + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax | A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk Chronic Lymphatic Leukemia | Recruiting | DEU | 0 |
NCT05244070 | Phase I | BMS-986403 + Cytarabine + Fludarabine | A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Terminated | USA | ESP | 0 |
NCT05254743 | Phase III | Ibrutinib Pirtobrutinib | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 13 |
NCT05256641 | Phase Ib/II | Acalabrutinib | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05275504 | Phase I | TT-01488 | Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies | Recruiting | USA | 0 |
NCT05336812 | Phase II | Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT05360238 | Phase Ib/II | MB-106 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | Recruiting | USA | 0 |
NCT05388006 | Phase II | Acalabrutinib + Durvalumab + Venetoclax | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT05405309 | Phase Ib/II | Olaparib + RP-3500 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL) | Suspended | USA | 0 |
NCT05424822 | Phase I | JNJ-80948543 | A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | FRA | AUS | 3 |
NCT05536349 | Phase II | Obinutuzumab + Pirtobrutinib + Venetoclax | Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | Recruiting | USA | 0 |
NCT05602363 | Phase I | AS-1763 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05624554 | Phase III | Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab ARQ 531 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | Recruiting | USA | AUS | 14 |
NCT05650723 | Phase II | Venetoclax + Zanubrutinib Obinutuzumab + Venetoclax + Zanubrutinib | Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab | Recruiting | USA | 0 |
NCT05665062 | Phase I | Cyclophosphamide + Fludarabine STK-009 + SYNCAR-001 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT05665530 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | ITA | CAN | AUS | 1 |
NCT05677919 | Phase II | Pirtobrutinib + Venetoclax | Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia, MIRACLE Study | Recruiting | USA | 0 |
NCT05702853 | Phase Ib/II | CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | Not yet recruiting | USA | 0 |
NCT05718869 | Phase II | Tafasitamab-cxix + Zanubrutinib | Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study | Recruiting | USA | 0 |
NCT05753501 | Phase I | ABBV-101 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Recruiting | USA | 2 |
NCT05780034 | Phase I | AC0676 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Recruiting | USA | 0 |
NCT05797233 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | Recruiting | USA | 0 |
NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Recruiting | USA | AUS | 0 |
NCT05947851 | Phase III | Rituximab + Venetoclax ARQ 531 + Venetoclax | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) | Recruiting | USA | AUS | 4 |
NCT05950165 | Phase Ib/II | CHO-H01 | A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | Recruiting | USA | 1 |
NCT05963217 | Phase I | Cyclophosphamide + Fludarabine TBI-2001 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL | Recruiting | CAN | 0 |
NCT05967416 | Phase I | SIRPant-M | Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Not yet recruiting | USA | 0 |
NCT05983965 | Phase I | Tazemetostat Acalabrutinib + Tazemetostat | Phase I Study of Tazemetostat in Lymphoid Malignancies | Not yet recruiting | USA | 0 |